Analysts trim price targets for Bicycle Therapeutics, Haleon and Lloyds

what happened

According to TradingView, citing FactSet data, analysts have modestly reduced average 12-month price targets for three companies. For Bicycle Therapeutics, the average target slipped from $10.14 to $9.86 across seven analysts, with forecasts spanning $5 to $14. Relative to the October 28 close, the updated target implies roughly 154% potential upside.

For Haleon, the average target fell from $11.15 to $11.07 across 16 analysts, implying about 11% upside. For Lloyds Banking Group, the target dropped from $6.78 to $6.73 across 19 analysts, implying about 22% upside.

The consensus rating for all three stocks remains Buy. Bicycle has 7 Buy, 3 Hold and no Sell ratings among 10 covering analysts; Haleon has 11 Buy, 5 Hold and 2 Sell out of 18; Lloyds has 12 Buy, 7 Hold and 2 Sell out of 21.

why it matters

Revisions of this kind are usually routine: a shift of a dollar or two in the average target and small changes to the forecast range rarely move the market on their own. Investors tend to focus more on actual company results and management commentary. These figures reflect analyst opinion and are not investment advice.

tags

instruments